We present this case to (1) alert clinicians to potential complications when patch-testing patients with pemphigus and other immunobullous disorders and (2) review documented adverse events or ...

The term “pemphigus” refers to a group of organ-specific, rare, autoimmune diseases that cause blistering of the skin. Pemphigus foliaceus (PF) is the second most common form of pemphigus. It is ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...

The three main types of pemphigus are vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. a) Pemphigus vulgaris is the most common variety and accounts for 70% of the pemphigus cases. It is ...

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Shares of argenx SE ARGX were down 25.1% on Dec 20 after the company announced top-line data from the phase III ADDRESS study, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and ...

Please provide your email address to receive an email when new articles are posted on . A trial of adjuvant immunoadsorption for pemphigus diseases was ended early due to adverse events. The time to ...

Desmoglein 1 is the target antigen and probably the initiating immunogen of the autoantibody response in pemphigus foliaceus (PF), a blistering autoimmune skin disease. We previously showed that the ...

BOSTON--(BUSINESS WIRE)--Syntimmune, Inc., a clinical-stage biotechnology company developing antibody therapeutics targeting FcRn, today announced positive preliminary results from its Phase 1b ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Pemphigus is the term used to describe a group of autoimmune diseases that cause the skin and mucous membranes to become blistered. The conditions may therefore affect areas of the body such as the ...